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Chronic tinnitus is characterized by neuroplastic changes of the auditory cortex. A
promising method for therapy of chronic tinnitus is vagus nerve stimulation (VNS)
combined with auditory stimulation. The principle of VNS is reversal of pathological
neuroplastic changes of the auditory cortex toward physiological neural activity and
synchronicity. The VNS mechanism of action in chronic tinnitus patients is prevailingly
through the muscarinic neuromodulation of the auditory cortex by the activation of nc.
basalis Meynerti. The aim of this study is to propose potential pharmaceutics which
may improve the neuromodulatory effects of VNS. The working hypothesis is that
M1 receptors have a dominant role in the neural plasticity of the auditory cortex. We
propose that allosteric agonists of the muscarinic receptor type 1 (M1) receptor could
improve specificity and selectivity of the neuromodulatory effect of VNS on the auditory
cortex of chronic tinnitus patients even in the circumstances of lower acetylcholine
brain concentration. This intervention would also reinforce the re-learning process of
tinnitus (sub)networks by acting on cholinergic memory and learning mechanisms. We
performed in silico screening of drug space using the EIIP/AQVN filter and selected
50 drugs as candidates for allosteric modulators of muscarinic receptors. Further
filtering of these compounds by means of 3D QSAR and docking revealed 3 approved
drugs—bromazepam, estazolam and flumazenil as the most promising candidates for
combined chronic tinnitus therapy. These drugs should be further evaluated by biological
tests and clinical trials.
Keywords: tinnitus, muscarinic allosteric agonists, M1 receptor, vagus nerve stimulation, in silico analysis,
information spectrum method
INTRODUCTION
Tinnitus, the perception of phantom sound, is a debilitating condition with notable prevalence:
approximately 10–15% of the general population experience tinnitus and for 7 million this is a
debilitating condition (Geven et al., 2014). The Royal National Institute for Deaf People estimates
that 13 million people in Western Europe and USA seek medical assistance for their tinnitus
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symptoms (Vio and Holme, 2005). Demographic development
and increase of occupational and ambient noise support the view
that this problem will be even more prevalent in the future. In
spite of the fact that more than 4million prescriptions are written
for the treatment of tinnitus, there is not a single drug approved
by the FDA specific for the treatment of tinnitus. The estimates
are that a potential tinnitus drug could have a product value of
more than $600 million in the first year after its release (https://
www.ata.org/understanding-facts).
The problem of chronic tinnitus is mainly of central origin.
The pathophysiological substrate of chronic tinnitus is still a
matter of intense debate (De Ridder et al., 2014b; Norena,
2015). The majority of chronic states of tinnitus begin with the
functional damage of the cochlea (i.e., noise or hearing loss) and
consequent abnormal input to the higher level neural structures
of the auditory pathway (Eggermont and Roberts, 2004; Guitton,
2012; Chen et al., 2013; Wu et al., 2016). When tinnitus stabilizes
as a chronic condition (not less than 1 year, Malinvaud et al.,
2016), then numerous functional disarrangements occur, like the
hyperpolarization of thalamic relay cells (Llinas et al., 2005), the
changes in the central neural sensitivity or gain (Norena, 2011)
and the functional coupling of different parallel brain networks
(Kalauzi et al., 2012, 2014) into the “tinnitus (sub)network” (De
Ridder et al., 2014b). This finally results also with the functional
and anatomical disarrangement of the auditory cortex tonotopic
map (Norena and Eggermont, 2005; Guitton, 2012).
The central (Zoccoli et al., 2005; Bojic´ et al., 2016) and
peripheral components of the autonomic nervous system (Bojic´,
2003; Silvani et al., 2003; Platiša et al., 2016) play crucial
roles in the stabilization and manifestations of chronic tinnitus
(Jastreboff, 2011). Cholinergic innervation plays a major role
in the development and plasticity of the auditory cortex
(Shideler and Yan, 2010). The growth and functional coupling
of cholinergic innervations with auditory cortical cells goes
in parallel with the forming of thalamocortical connections
during embryological development and in the early stage after
the birth. The presence of muscarinic acetylcholine receptors
plays a crucial role in this process: muscarinic receptor type 1
(M1) regulates the expression of different neurotrophins (brain-
derived neurotrophic factor and nerve growth factor; Da Penha
Berzaghi et al., 1993; Betancourt et al., 2006), determines the
structure of neurons by promoting cell survival (Tobin and Budd,
2003) and stimulates the neural (VanDeMark et al., 2009) and
dendritic outgrowth (Zhang et al., 2005). Finally, muscarinic
antagonists decrease the frequency specific plasticity of the
auditory cortex in the paradigm of auditory fear conditioning
(Ji et al., 2005; Ji and Suga, 2009) and, importantly for this
concept, the stimulation of nc. basalis Meynerti (Bakin and
Weinberger, 1996; Weinberger, 2003). Nc. basalis Meynerti
electrical stimulation paired with tones acutely enhances cortical
neural plasticity and reverses the neurological and perceptual
correlates of tinnitus in adult animals (Nichols et al., 2011).
M1 impacts also the processes of learning and memory (Zhang
et al., 2006; Butcher et al., 2016) which are crucially important
for the genesis and maintenance of tinnitus (De Ridder et al.,
2014b; Eggermont and Kral, 2016; Vanneste and De Ridder,
2016).
Different techniques, both noninvasive and invasive, were
tested in order to reverse the pathological neuroplastic changes
of the auditory cortex toward the physiological state (Vanneste
and De Ridder, 2012). Vagus nerve stimulation paired with tone
stimulation is among the most promising tools for treatment
of chronic tinnitus (Engineer et al., 2011; Shetake et al., 2012;
De Ridder et al., 2014a). It is based on the principle of
provoking the central neuromodulatory responses by stimulation
of vagal afferent fibers and nc. basalis Meynerti which abundantly
innervate the auditory cortex. Vagus stimulation paired with tone
stimulation has an effect of targeted plasticity, the phenomenon
of reversing the map changes in individuals with tinnitus.
The area of tinnitus specific cortical neurons is consequently
diminished (Engineer et al., 2011). In human studies the
efficiency of this method to reduce tinnitus severity was around
40%, and interestingly, all the patients who did not experience
an improvement were on drug therapy that included, among
others, muscarinic antagonists (De Ridder et al., 2014a). More,
it is well-documented in the literature that M1 receptors have
a crucial role in the experience-dependent plasticity of the
auditory cortex (Shideler and Yan, 2010). Our hypothesis is
that in silico identification of M1 receptor allosteric agonists
would propose a new line for the clinical research for modulated
vagus nerve stimulation (VNS) paired with tones, potentially
more targeted and more efficient. In addition, by agonizing
the cholinergic mechanisms of learning and memory, attention,
stress response, wakefulness and sleep and sensory information
processing (Ferreira-Vieira et al., 2016), M1 allosteric agonists
would stabilize the process of re-learning of neural networks
involved in tinnitus perception. In order to choose the best
candidates for these drugs we applied in silico strategies that
resulted with three candidates for M1 allosteric modulators.
METHODS
In this paper, we implemented a virtual screening protocol
that includes both short and long-range interactions between
interacting molecules. The long-range interactions are denoted
by the parameters—the average quasi valence number (AQVN)
and the electron-ion interaction potential (EIIP).
First, the EIIP/AQVN filter was applied for in silico screening
of the DrugBank (http://www.drugbank.ca) (Wishart et al., 2006)
and then followed by 3D QSAR and molecular docking for
identification of candidate allosteric modulators of M1.
EIIP/AQVN
The EIIP for organic molecules can be determined by the
following simple equation derived from the “general model
pseudopotential” (Veljkovic et al., 2011)
EIIP = 0.25 Z∗ sin(1.04 pi Z∗)/2pi (1)
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where Zi is the valence number of the ith atomic component, ni
is the number of atoms of the ith component,m is the number of
atomic components in the molecule, and N is the total number
of atoms. EIIP values calculated according to Equations (1, 2) are
expressed in Rydberg units (Ry).
Further filtering of these compounds was performed bymeans
of 3D QSAR(quantitative structure–activity relationships) in
Pentacle software and followed by docking.
3D QSAR
In order to build a pharmacophoric model and select compounds
based on their pharmacophoric similarity, 12 literature M1
modulators (Target ID CHEMBL216) were downloaded from
the ChEMBL database. All compounds were converted into the
SDF format and then imported, along with candidate compounds
into the Pentacle QSAR software, protonated at pH 7.4, and
oriented according to the principal moments of inertia. Standard
GRIND descriptors were calculated and the PCA model was
built. From PCA scores that included the first two major
components, PC1 and PC2, the most similar drug molecules
to literature allosteric modulators were selected for further
filtering.
Molecular Docking
Molecular docking of selected candidates was performed into the
built homology model of the M1 receptor. The binding site of
allosteric modulators was identified from the 4MQT structure
and was placed in between extracellular loops of the 2 and 3
region. The grid box for docking, with dimensions 20 × 20 ×
20 Å was placed to occupy this space. The receptor and ligands
were prepared in Autodock Tools 1.5.6. Docking was carried out




The virtual screening (VS) protocol in this study was based on
the application of consecutive filters to select candidate allosteric
modulators of M1. Previously it was shown for molecular
targets in diverse pathological states that small molecules with
similar AQVN and EIIP values interact with the common
therapeutic agent (Veljkovic et al., 2011, 2013). This resulted in
determining criteria for virtual screening of molecular libraries
for compounds with similar therapeutic properties (Veljkovic
et al., 2013). The selected learning set consisted of allosteric
agonists and positive allosteric modulators of M1, reported in
literature (Conn et al., 2009). The compounds from the learning
set were inside the active domain with AQVN and EIIP values
within the intervals of (3–3.08) and (0.004–0.073), respectively,
and this domain was selected as a criterion for the selection of
compounds representing candidate allosteric modulators of M1
(Figure 1). By applying the EIIP/AQVN-based virtual screening
criterion, 50 drugs were chosen out of 1463 approved drugs
from the DrugBank (http://www.drugbank.ca) (Wishart et al.,
2006).
FIGURE 1 | Schematic presentation of the EIIP/AQVN criterion for selection of
candidate allosteric modulators of muscarinic receptor M1. Active domain
(red): AQVN (3–3.08), EIIP (0.004–0.073). Chemical space (blue) AQVN
(2.40–3.30) EIIP (0.000–0.116) EIIP/AQVN domain of homologous distribution
of >90% compounds from PubChem Compound Database.
QSAR Selection
The 103 molecules after EIIP filtering were subjected to
pharmacophoring modeling and selection. Twelve literature M1
modulators were converted into 3D structures, along with drug
candidates and GRIND descriptors for all compounds were
calculated, from which a PCA model was built (Table 1).
From PCA scores that included the first two major
components, PC1 and PC2, based on their vicinity in
the PC1-PC2 space to literature M1 modulators, the most
pharmacologically similar drug molecules were selected. The
QSAR filtering was carried in Pentacle software (Duran et al.,
2009). Finally, 10 compounds were selected for molecular
docking (Table 2).
M1 Muscarinic Receptor Homology
Modeling
In order to obtain the relevant structure of theM1 receptor active
state, the crystal structure of the M2 muscarinic receptor in the
active state with the agonist and allosteric modulator (PDB ID
4MQT) was used as a template for homology modeling. The
P11229 sequence of the Homo sapiens muscarinic acetylcholine
receptor M1 was used. The modeling was carried out on the
Protein Homology/analogY Recognition Engine V 2.0 (Phyre)
server (Kelley et al., 2015).
Molecular Docking
Ten selected compounds after 3D QSAR were further subjected
to molecular docking into the M1 receptor model. Three
compounds with the lowest binding energy values (Table 2)
and identified hydrophilic and hydrophobic interactions with
allosteric binding site amino acid residues (Tyr 82, Tyr 85,
Tyr 106, Tyr 179, Trp 400, Glu 401) were selected to be
the best candidates, along with considerations of drug side
effects and purpose. Finally, BROMAZEPAM, ESTAZOLAM,
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TABLE 1 | PCA models for M1 alosteric modulators and candidates.
Component SSX SSXacc VarX VarXacc
1 44.48 44.48 43.92 43.92
2 11.32 55.8 10.98 54.9
3 5.48 61.29 5.19 60.09
4 4.97 66.26 4.77 64.86
5 4.09 70.35 3.94 68.8
SSX, Percentage of the X sum of squares; SSXacc, accumulative percentage of the X
sum of squares; VarX, percentage of the X variance; VarXaac, accumulative percentage
of the X variance.
TABLE 2 | QSAR selection of 10 compounds for molecular docking, with docking
energies.












and FLUMAZENIL were found to be the best promising
candidates (Figures 2–4, respectively).
DISCUSSION
We hypothesized that allosteric activation of M1 receptors in the
circumstances of increased cholinergic neurotransmission to the
auditory cortex by targeted VNS, will provoke an increase of M1
mediated effects:
(1) Neuromodulatory action of BDGF and NGF (Da Penha
Berzaghi et al., 1993) in neuronal zones adjacent to the
tinnitus;
(2) Neuromodulatory action on frequency specific neuronal
zones enabling the recruitment of pathologically active
neurons back to the physiological pattern of activity;
(3) Regaining the physiological tonotopy (Zhang et al., 2006) of
the auditory cortex;
(4) Recruitment of novel neurons from undifferentiated
neuronal pools in the hippocampus (VanDeMark et al.,
2009) and
(5) The dendritic and axonal “rewiring” of the tinnitus
“subnetwork” (De Ridder et al., 2014b).
The AQVN/EIIP approach was applied previously for the
selection of new candidates in pharmacotherapy of the vasovagal
syncope (VVS) revealing that the majority of antimuscarinic
drugs might have a therapeutical potential for VVS. In this
FIGURE 2 | Bromazepam in allosteric modulator binding region of M1
acetylcholine receptor, with marked aminoacids, and intermolecular
interactions. Green: hydrogen bonds, purple: hydrophobic interactions.
FIGURE 3 | Estazolam in allosteric modulator binding region of M1
acetylcholine receptor, with marked aminoacids, and intermolecular
interactions. Green: hydrogen bonds, purple: hydrophobic interactions.
study sequential virtual screening criteria were applied, first the
AQVN/EIIP based filter for the selection of candidate allosteric
agonists of the M1 receptor selecting 50 drugs out of 1463
approved drugs from the DrugBank (http://www.drugbank.ca;
Wishart et al., 2006). This step was followed by 3DQSAR analysis
and finally docking. The screening identified bromazepam,
estazolam, and flumazenil as the most promising drugs which
could be repurposed as allosteric agonists of the M1 receptor.
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FIGURE 4 | Flumazenil in allosteric modulator binding region of M1
acetylcholine receptor, with marked aminoacids, and intermolecular
interactions. Green: hydrogen bonds, purple: hydrophobic interactions.
Bromazepam and estazolam are known anti-anxiety
agents with a hypnotic effect. Flumazenil has specific
antibenzodiazepine action and is used as an antihypnotic agent in
circumstances where the benzodiazepine and nonbenzodizepine
hypnotic effect has to be reduced.
If we expand the concept to other methods of treatment of
tinnitus (invasive or noninvasive; Vanneste andDe Ridder, 2012),
it is reasonable to propose that pharmacological facilitation
of neuromodulatory changes by the in silico identified drugs
in our investigation in tinnitus network structures would be
beneficial even in these treatments. Future clinical studies of the
combinedM1 allosteric agonist therapy with VNS and potentially
other invasive and noninvasive methods of chronic tinnitus
treatment will reveal the final answer regarding their synergistic
action.
Learning during wakefulness induces neural plasticity
changes. Their stabilization occurs during sleep (Tononi and
Cirelli, 2005). The process of sleep selects the synaptic weights
of the neural synapses on the basis of their engagement during
wakefulness: if the synapses are more used, the sleep process
will make them more stabile while the less used synapses during
wakefulness will not be strengthened. This is at least partially
due to the intensity of cholinergic neurotransmission that
increases from wakefulness toward NREM and REM sleep
(Hobson and Friston, 2012). The last phase, REM, also known
as a dream state, is the state of consciousness where tinnitus
is not perceived (De Ridder et al., 2014b). The sleep process
in this way supports the mechanisms of learning and memory
acquired during wakefulness. If we presume that VNS paired
with tones is also the process of re-learning of the cortical
networks pathologically changed in tinnitus, then the quality
of sleep in chronic tinnitus patients is essential for stabilization
of daily acquired neuroplastic changes by the VNS therapy. In
line with that, the cholinergic effect together with the hypnotic
effect of the proposed drugs could be beneficial and their
application justified before bedtime. The caveat that has to be
taken into consideration is the feature of benzodiazepines to
promote or to reinforce already existing sleep apnea by increased
miorelaxation. This effect could diminish the amount of both
NREM and REM sleep and potentially prevent the beneficial
effect of the sleep on the process of the recovery in tinnitus
patients. Biological experiments will address the question of
concentration applied to the treatment of tinnitus and the
question if sleep apnea as the contraindication for application of
the proposed M1 allosteric agonists.
In conclusion, the results presented here suggest a potential
novel approach in treatment of chronic tinnitus by VNS paired
with tones with in silico repurposed drugs as therapeutic
candidates that may target M1 and prospectively improve the
treatment.
AUTHOR CONTRIBUTIONS
TB, VP, MS, and SG contributed equally to the conception
of the work, acquisition, analysis, and interpretation of data.
TB, VP, and SG participated in drafting the manuscript,
revisiting it critically and gave final approval of the version
to be published. The authors reached the agreement to
be accountable for all the aspects of the work in ensuring
that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and
resolved.
ACKNOWLEDGMENTS
This work was financed by theMinistry of Education, Science and
Technological Development of the Republic of Serbia, project
III 41028 and 173001. The preliminary results of this article
presented at 10th International Tinnitus Research Initiative
Conference and 1st EU COST action (TINNET) Conference.
Tinnitus: subtypes, mechanisms and interventions, 16–18th
March 2016, Nottingham, UK were awarded by MRC Institute
of Hearing Research Early Career Award.
REFERENCES
Bakin, J. S., andWeinberger, N. M. (1996). Induction of a physiological memory in
the cerebral cortex by stimulation of the nucleus basalis. Proc. Natl. Acad. Sci.
U.S.A. 93, 11219–11224. doi: 10.1073/pnas.93.20.11219
Betancourt, A. M., Burgess, S. C., and Carr, R. L. (2006). Effect
of developmental exposure to chlorpyrifos on the expression
of neurotrophin growth factors and cell-specific markers in
neonatal rat brain. Toxicol. Sci. 92, 500–506. doi: 10.1093/toxsci/
kfl004
Frontiers in Neuroscience | www.frontiersin.org 5 November 2017 | Volume 11 | Article 636
Bojic´ et al. M1 Candidates-Potential Tinnitus Therapeutics
Bojic´, T. (2003). Mechanisms Of Cardiovascular Control And Effects Of Acoustic
Stimulation On Cardiovascular System During The Wake-Sleep Cycle. Ph.D.
Dissertation, Alma Mater Università di Bologna.
Bojic´, T., Perovic´, V., and Glišic´, S. (2016). In silico therapeutics for
neurogenic hypertension and vasovagal syncope. Front. Neurosci. 9:520.
doi: 10.3389/fnins.2015.00520
Butcher, A. J., Bradley, S. J., Prihandoko, R., Brooke, S. M., Mogg, A., Bourgognon,
J. M., et al. (2016). An antibody biosensor establishes the activation of the M1
muscarinic acetylcholine receptor during learning and memory. J. Biol. Chem.
291, 8862–8875. doi: 10.1074/jbc.M115.681726
Chen, G. D., Stolzberg, D., Lobarinas, E., Sun, W., Ding, D., and Salvi, R. (2013).
Salicylate-induced cochlear impairments, cortical hyperactivity and re-tuning,
and tinnitus. Hear. Res. 295, 100–113. doi: 10.1016/j.heares.2012.11.016
Conn, P. J., Jones, C. K., and Lindsley, C. W. (2009). Subtype-selective allosteric
modulators of muscarinic receptors for the treatment of CNS disorders. Trends
Pharmacol. Sci. 30, 148–155. doi: 10.1016/j.tips.2008.12.002
Da Penha Berzaghi, M., Cooper, J., Castren, E., Zafra, F., Sofroniew, M., Thoenen,
H., et al. (1993). Cholinergic regulation of brain-derived neurotrophic factor
(BDNF) and nerve growth factor (NGF) but not neurotrophin-3 (NT-3) mRNA
levels in the developing rat hippocampus. J. Neurosci. 13, 3818–3826.
De Ridder, D., Vanneste, S., Engineer, N. D., and Kilgard, M. P. (2014a). Safety
and efficacy of vagus nerve stimulation paired with tones for the treatment of
tinnitus: a case series. Neuromodulation 17, 170–179. doi: 10.1111/ner.12127
De Ridder, D., Vanneste, S., Weisz, N., Londero, A., Schlee, W., Elgoyhen, A. B.,
et al. (2014b). An integrative model of auditory phantom perception: tinnitus
as a unified percept of interacting separable subnetworks. Neurosci. Biobihav.
Rev. 44, 16–32. doi: 10.1016/j.neubiorev.2013.03.021
Duran, A., Zamora, I., and Pastor, M. (2009). Suitability of GRIND-based principal
properties for the description of molecular similarity and ligand-based virtual
screening. J. Chem. Inf. Model. 49, 2129–2138. doi: 10.1021/ci900228x
Eggermont, J. J., and Kral, A. (2016). Somatic memory and gain increase as
preconditions for tinnitus: insights from congenital deafness. Hear. Res. 333,
37–48. doi: 10.1016/j.heares.2015.12.018
Eggermont, J. J., and Roberts, L. E. (2004). The neuroscience of tinnitus. Trends
Neurosci. 27, 676–682. doi: 10.1016/j.tins.2004.08.010
Engineer, N. D., Riley, J. R., Seale, J. D., Vrana, W. A., Shetake, J. A., Sudanagunta,
S. P., et al. (2011). Reversing pathological neural activity using targeted
plasticity. Nature 470, 101–104. doi: 10.1038/nature09656
Ferreira-Vieira, T. H., Guimaraes, I. M., Silva, F. R., and Ribeiro, F. M. (2016).
Alzheimer’s disease: targeting the cholinergic system. Curr. Neuropharmacol.
14, 101–115. doi: 10.2174/1570159X13666150716165726
Geven, L. I., De Kleine, E.,Willemsen, A. T., and VanDijk, P. (2014). Asymmetry in
primary auditory cortex activity in tinnitus patients and controls. Neuroscience
256, 117–125. doi: 10.1016/j.neuroscience.2013.10.015
Guitton, M. J. (2012). Tinnitus: pathology of synaptic plasticity at the cellular and
system levels. Front. Syst. Neurosci. 6:12. doi: 10.3389/fnsys.2012.00012
Hobson, J. A., and Friston, K. J. (2012). Waking and dreaming consciousness:
neurobiological and functional considerations. Prog. Neurobiol. 98, 82–98.
doi: 10.1016/j.pneurobio.2012.05.003
Jastreboff, P. (2011). “Tinnitus retraining therapy,” in Textbook of Tinnitus, eds A.
Moller, B. Langguth, D. De Ridder, and T. Kleinjung (New York, NY: Springer),
575–596.
Ji, W., and Suga, N. (2009). Tone-specific and nonspecific plasticity of
inferior colliculus elicited by pseudo-conditioning: role of acetylcholine
and auditory and somatosensory cortices. J. Neurophysiol. 102, 941–952.
doi: 10.1152/jn.00222.2009
Ji, W., Suga, N., and Gao, E. (2005). Effects of agonists and antagonists of
NMDA and ACh receptors on plasticity of bat auditory system elicited by fear
conditioning. J. Neurophysiol. 94, 1199–1211. doi: 10.1152/jn.00112.2005
Kalauzi, A., Vuckovic, A., and Bojic, T. (2012). EEG alpha phase shifts during
transition from wakefulness to drowsiness. Int. J. Psychophysiol. 86, 195–205.
doi: 10.1016/j.ijpsycho.2012.04.012
Kalauzi, A., Vuckovic, A., and Bojic, T. (2014). Topographic distribution of EEG
alpha attractor correlation dimension values in wake and drowsy states in
humans. Int. J. Psychophysiol. 95, 278–291. doi: 10.1016/j.ijpsycho.2014.11.008
Kelley, L. A., Mezulis, S., Yates, C.M.,Wass, M. N., and Sternberg, M. J. (2015). The
phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc.
10, 845–858. doi: 10.1038/nprot.2015.053
Llinas, R., Urbano, F. J., Leznik, E., Ramirez, R. R., and Van Marle, H. J. (2005).
Rhythmic and dysrhythmic thalamocortical dynamics: GABA systems and the
edge effect. Trends Neurosci. 28, 325–333. doi: 10.1016/j.tins.2005.04.006
Malinvaud, D., Londero, A., Niarra, R., Peignard, P., Warusfel, O., Viaud-Delmon,
I., et al. (2016). Auditory and visual 3D virtual reality therapy as a new treatment
for chronic subjective tinnitus: results of a randomized controlled trial. Hear.
Res. 333, 127–135. doi: 10.1016/j.heares.2015.12.023
Nichols, J. A., Nichols, A. R., Smirnakis, S. M., Engineer, N. D., Kilgard, M. P., and
Atzori, M. (2011). Vagus nerve stimulation modulates cortical synchrony and
excitability through the activation of muscarinic receptors. Neuroscience 189,
207–214. doi: 10.1016/j.neuroscience.2011.05.024
Norena, A. (2011). An integrative model of tinnitus based on a central
gain controlling neural sensitivity. Neurosci. Biobehav. Rev. 35, 1089–1109.
doi: 10.1016/j.neubiorev.2010.11.003
Norena, A. (2015). Revisiting the cochlear and central mechanisms of tinnitus and
therapeutic approaches. Audiol. Neurootol. 20, 53–59. doi: 10.1159/000380749
Norena, A. J., and Eggermont, J. J. (2005). Enriched acoustic environment after
noise trauma reduces hearing loss and prevents cortical map reorganization. J.
Neurosci. 25, 699–705. doi: 10.1523/JNEUROSCI.2226-04.2005
Platiša, M.M., Bojic´, T., Pavlovic´, S. U., Radovanovic´, N. N., and Kalauzi, A. (2016).
Generalized poincare plots-a new method for evaluation of regimes in cardiac
neural control in atrial fibrillation and healthy subjects. Front. Neurosci. 10:38.
doi: 10.3389/fnins.2016.00038
Shetake, J. A., Engineer, N. D., Vrana, W. A., Wolf, J. T., and Kilgard, M.
P. (2012). Pairing tone trains with vagus nerve stimulation induces
temporal plasticity in auditory cortex. Exp. Neurol. 233, 342–349.
doi: 10.1016/j.expneurol.2011.10.026
Shideler, K. K., and Yan, J. (2010). M1 muscarinic receptor for the development of
auditory cortical function.Mol. Brain 3:29. doi: 10.1186/1756-6606-3-29
Silvani, A., Bojic, T., Cianci, T., Franzini, C., Lodi, C. A., Predieri, S., et al. (2003).
Effects of acoustic stimulation on cardiovascular regulation during sleep. Sleep
26, 201–205. doi: 10.1093/sleep/26.2.201
Tobin, A. B., and Budd, D. C. (2003). The anti-apoptotic response of the Gq/11-
coupled muscarinic receptor family. Biochem. Soc. Trans. 31, 1182–1185.
doi: 10.1042/bst0311182
Tononi, G., and Cirelli, C. (2005). “A possible role of sleep in synaptic
homeostasis,” in The Physiological Nature of Sleep, eds P. L. Parmeggiani and
R. Velluti (London: Imperial College Press), 77–103.
Trott, O., and Olson, A. J. (2010). AutoDock vina: improving the speed and
accuracy of docking with a new scoring function, efficient optimization, and
multithreading. J. Comput. Chem. 31, 455–461. doi: 10.1002/jcc.21334
VanDeMark, K. L., Guizzetti, M., Giordano, G., and Costa, L. G. (2009). The
activation ofM1muscarinic receptor signaling induces neuronal differentiation
in pyramidal hippocampal neurons. J. Pharmacol. Exp. Ther. 329, 532–542.
doi: 10.1124/jpet.108.150128
Vanneste, S., andDe Ridder, D. (2012). Noninvasive and invasive neuromodulation
for the treatment of tinnitus: an overview. Neuromodulation 15, 350–360.
doi: 10.1111/j.1525-1403.2012.00447.x
Vanneste, S., and De Ridder, D. (2016). Deafferentation-based pathophysiological
differences in phantom sound: tinnitus with and without hearing loss.
Neuroimage 129, 80–94. doi: 10.1016/j.neuroimage.2015.12.002
Veljkovic, N., Glisic, S., Perovic, V., and Veljkovic, V. (2011). The role of long-
range intermolecular interactions in discovery of new drugs. Expert Opin. Drug
Discov. 6, 1263–1270. doi: 10.1517/17460441.2012.638280
Veljkovic, N., Glisic, S., Prljic, J., Perovic, V., and Veljkovic, V. (2013). Simple and
general criterion for “in silico” screening of candidate HIV drugs. Curr. Pharm.
Biotechnol. 14, 561–569. doi: 10.2174/138920101405131111105301
Vio, M. M., and Holme, R. H. (2005). Hearing loss and tinnitus: 250 million
people and a US$10 billion potential market. Drug Discov. Tod. 10, 1263–1265.
doi: 10.1016/S1359-6446(05)03594-4
Weinberger, N. M. (2003). The nucleus basalis and memory codes: auditory
cortical plasticity and the induction of specific, associative behavioral
memory. Neurobiol. Learn. Mem. 80, 268–284. doi: 10.1016/S1074-7427(03)
00072-8
Wishart, D. S., Knox, C., Guo, A. C., Shrivastava, S., Hassanali, M., Stothard,
P., et al. (2006). DrugBank: a comprehensive resource for in silico drug
discovery and exploration.Nucleic Acids Res. 34, D668–D672. doi: 10.1093/nar/
gkj067
Frontiers in Neuroscience | www.frontiersin.org 6 November 2017 | Volume 11 | Article 636
Bojic´ et al. M1 Candidates-Potential Tinnitus Therapeutics
Wu, C., Stefanescu, R. A., Martel, D. T., and Shore, S. E. (2016). Tinnitus:
maladaptive auditory-somatosensory plasticity. Hear. Res. 334, 20–29.
doi: 10.1016/j.heares.2015.06.005
Zhang, Y., Dyck, R. H., Hamilton, S. E., Nathanson, N. M., and Yan,
J. (2005). Disrupted tonotopy of the auditory cortex in mice lacking
M1 muscarinic acetylcholine receptor. Hear. Res. 201, 145–155.
doi: 10.1016/j.heares.2004.10.003
Zhang, Y., Hamilton, S. E., Nathanson, N. M., and Yan, J. (2006). Decreased
input-specific plasticity of the auditory cortex in mice lacking M1
muscarinic acetylcholine receptors. Cereb. Cortex 16, 1258–1265.
doi: 10.1093/cercor/bhj067
Zoccoli, G., Bojic´, T., and Franzini, C. (2005). “Regulation of cerebral
circulation during sleep,” in The Physiological Nature of Sleep, 1st Edn.,
eds P. L. Parmeggiani and R. Velluti (London: Imperial College Press),
351–369.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Bojic´, Perovic´, Senc´anski and Glišic´. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 7 November 2017 | Volume 11 | Article 636
